Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| XENON PHARMACEUTICALS | 22 | - | +0,93 % | ||
| REGENERON PHARMACEUTICALS | 8 | 22 | -0,71 % | ||
| EDITAS MEDICINE | 8 | - | +2,24 % | ||
| UNITED THERAPEUTICS | 7 | 8 | -1,34 % | ||
| ZEVRA THERAPEUTICS | 7 | 1 | -16,40 % | ||
| DYNE THERAPEUTICS | 7 | - | 0,00 % | ||
| ARS PHARMACEUTICALS | 7 | - | -0,22 % | ||
| SEPTERNA | 6 | 16 | 0,00 % | ||
| COHERUS ONCOLOGY | 6 | 1 | -1,68 % | ||
| UNIQURE | 6 | - | -0,26 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03:12 | Vertex Reports Positive Phase 3 Trial Results For Povetacicept In IgA Nephropathy; Stock Up | 187 | AFX News | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial evaluating... ► Artikel lesen | |
| 02:06 | Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates | 1 | Seeking Alpha | ||
| 01:18 | Cathie Wood's ARK trims 10X Genomics stock, adds DraftKings | 3 | Investing.com | ||
| 00:42 | Zevra targets expanded patient reach with 52 annual MIPLYFFA enrollments while advancing European access | 4 | Seeking Alpha | ||
| Mo | Vertex kidney disease drug hits mark in late-stage study | 5 | BioPharma Dive | ||
| Mo | Vera Therapeutics stock rating reaffirmed at Buy by BofA Securities | 2 | Investing.com | ||
| Mo | MESOBLAST LIMITED: Appendix 3Y for Gregory George | - | ASX | ||
| Mo | Axsome Therapeutics: Wachstumsstrategie und Pipeline im Fokus der Leerink-Konferenz | 1 | Investing.com Deutsch | ||
| Mo | Baird bestätigt Rating für Editas Medicine nach Fortschritten in der Pipeline | 1 | Investing.com Deutsch | ||
| Mo | Immunocore stellt auf Leerink-Konferenz Wachstumsstrategie und Innovationen vor | 2 | Investing.com Deutsch | ||
| Mo | Baird reiterates Editas Medicine stock rating on pipeline progress | 1 | Investing.com | ||
| Mo | UNITED THERAPEUTICS Corp - 8-K, Current Report | 1 | SEC Filings | ||
| Mo | Barclays reiterates Jazz Pharmaceuticals stock rating on CNS strength | 2 | Investing.com | ||
| Mo | Ionis Pharmaceuticals skizziert Strategie für 2026: TRYNGOLZA-Expansion und wichtige Studiendaten im Fokus | 1 | Investing.com Deutsch | ||
| Mo | Septerna, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| Mo | Vera Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Mo | Coherus Oncology, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| Mo | Editas Medicine, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| Mo | Zevra Therapeutics: EPS übertrifft Schätzungen um 0,14 $ - Umsatz besser als erwartet | 5 | Investing.com Deutsch | ||
| Mo | Coherus Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.